Friday, December 11, 2009

How open innovation could reinvigorate the pharmaceutical industry with fresh R&D opportunities

Thomas Senderovitz recently wrote an editorial entitled "How open innovation could reinvigorate the pharmaceutical industry with fresh R&D opportunities." Read the article here.

He brings up several interesting observations about the current state of innovation in the Pharmaceutical market:
-Pharma innovation is often divided into therapeutic innovation and pharmacological innovation
-The cost of bringing new medicines to patients has increased dramatically over recent decades, while productivity has declined
-The pharmaceutical industry has done little to innovate their business model


The article also states:
The best innovative activity occurs when everyone - researchers, companies, government and nongovernment organizations - work together to ensure that new ideas reach public, but are appropriately regulated and efficiently delivered to those who need them.

What are your comments on this? Does the Pharma industry need to change their model? Should more players than just the Pharma companies and CROs work together to create new ideas and bring them to the public?

Mr. Senderovitz will be a keynote speaker at Partnerships in Clinical Trials 2010. For more information, visit the 19th Annual Partnerships in Clinical Trails Webpage.

No comments:

Clicky Web Analytics